))
Unanswered questions regarding the sequencing of BCMA therapies, the prognostic value of CTCs & the growing role of quadruplets
Manage episode 396148907 series 2838329
Innhold levert av VJHemOnc. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av VJHemOnc eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
The treatment and management of patients with multiple myeloma is continually evolving, giving rise to novel prognostic tools and therapeutic options, with associated benefits and challenges. Several ongoing clinical trials in the field are investigating potential treatment approaches and addressing many unanswered questions.
In this podcast, Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, and Benjamin Derman, MD, University of Chicago, Chicago, IL, discuss several interesting topics in myeloma, including the challenges associated with sequencing anti-BCMA therapies, the prognostic value of circulating tumor cells (CTCs), and the growing role of quadruplet therapies in myeloma, with updates in this space from the 2023 ASH Annual Meeting.
200 episoder
Del
